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Abstract
Using a Cre/loxP system, we have determined the phenotypic consequences attributable to in vivo deletion of both
Rb1 and Trp53 in the mouse adrenal medulla. The coablation of these two tumor suppressor genes during embryo-
genesis did not disrupt adrenal gland development but resulted in the neoplastic transformation of the neural
crest–derived adrenal medulla, yielding pheochromocytomas (PCCs) that developed with complete penetrance
and were inevitably bilateral. Despite their typically benign status, these PCCs had profound ramifications on
mouse vitality, with effected mice having a median survival of only 121 days. Evaluation of these PCCs by both
immunohistochemistry and electron microscopy revealed that most Rb1−/−:Trp53−/− chromaffin cells possessed
atypical chromagenic vesicles that did not seem capable of appropriately storing synthesized catecholamines. The
structural remodeling of the heart in mice harboring Rb1−/−:Trp53−/− PCCs suggests that the mortality of these
mice may be attributable to the inappropriate release of catecholamines from the mutated adrenal chromaffin
cells. On the basis of the collective data from Rb1 and Trp53 knockout mouse models, it seems that the conversion
of Rb1 loss–driven adrenal medulla hyperplasia to PCC can be greatly enhanced by the compound loss of Trp53,
whereas the loss of Trp53 alone is generally ineffectual on adrenal chromaffin cell homeostasis. Consequently, the
Trp53 tumor suppressor gene is an efficient genetic modifier of Rb1 loss in the development of PCC, and their
compound loss in the adrenal medulla has a profound impact on both cellular homeostasis and animal vitality.
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Introduction
Development and cellular homeostasis necessitates the orchestrated
interplay of oncogene and tumor suppressor gene functions. Disrup-
tion of this delicate interaction can lead to transformation, and an in-
tegral event in this process is the escape of the cell cycle from normal
regulatory constraints.
The cell cycle is driven by the activity of the cyclin-dependent kinase
(Cdk)–cyclin complexes that phosphorylate and modify target pro-
teins to facilitate cell cycle progression. Consequently, the mainte-
nance of cellular homeostasis dictates that Cdk-cyclin function is
stringently regulated. This occurs by a number of diverse mechanisms
ranging from the regulation of cyclin expression levels through to the
activity of the cyclin-dependent kinase inhibitors (CKIs), which are
divided into two subfamilies based on their substrate specificity. The
Ink4 CKIs (p15, p16, p18, and p19) inhibit Cdk4/6–cyclin D com-
plexes, whereas the less specific Cip1/Kip1 inhibitors (p21, p27, and
p57) bind a number of different Cdk-cyclins but only inhibit specific
combinations [1,2]. These different classes of CKIs act synergisti-
cally to suppress cell cycle progression by inhibiting Cdk-cyclin func-
tion [3,4].
The perturbation of Cdk-cyclin function seems to be essential in
pheochromocytoma (PCC), a catecholamine producing tumor derived
from the chromaffin cells of the adrenal medulla. Indeed, p16, p18,
Abbreviations: Cdk, cyclin-dependent kinase; CKI, cyclin-dependent kinase inhibitor;
floxed, loxP flanked; PCC, pheochromocytoma; PP, pocket protein; TEC, tyrosinase-
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and p27 CKIs have all been identified as tumor suppressors relevant
to this tumor type [5–7]. Furthermore, overexpression of cyclin D
or cyclin E has also been identified as having an oncogenic function
in PCC [6,8].
Some of the primary targets of Cdk-cyclins in cell cycle progression
are the pocket proteins (PPs), Rb1 (retinoblastoma), retinoblastoma-
like 1 (Rbl1, also known as p107), and retinoblastoma-like 2 (Rbl2,
also known as p130). The PPs constitute an important family of tumor
suppressors that regulate cell cycle progression. Although all PPs have
tumor suppressive function, the strength of this function varies for
each member of the family. Rb1 is generally regarded as having the
strongest tumor suppressive activity and, whereas both Rbl1 and
Rbl2 alone are competent in this regard [9–11], they seem to function
most strongly in synergy withRb1 [12,13]. The PPs are also key players
in tissue development, with cell autonomous and nonautonomous
roles in homeostasis [14]. Despite their functional redundancy, the in-
teractions of the PPs are complex because different members can fulfill
diametrically opposed functions during development, as typified in
adipose tissue and skeletal muscle [15–17].
In mice younger than 6 months, Rb1 loss contributes significantly
to adrenal cell hyperplasia, which is an intermediate step to PCC,
although PCC can be observed in older Rb1+/− mice [18,19]. In this
context, the transition from hyperplasia to PCC is seen to have oc-
curred when the hyperplastic cells occupy greater than 50% of the
adrenal volume and they have started to either compress or invade
the cortex [20]. In humans, Rb1 loss is relatively common in PCC
but is an early event in the tumorigenic cascade, requiring further ge-
netic modifications to facilitate neoplastic transformation of hyper-
plastic cells [21]. It is known from murine models that the loss of
Rbl2, but not Rbl1, may serve as an important modifier of Rb1 [22].
In this study, we show that the Trp53 tumor suppressor gene is also an
efficient genetic modifier of Rb1 loss in the development of PCC.
Materials and Methods
Mice, Genotyping, and Strain Considerations
All mice were treated in accordance with the Australian Govern-
ment National Health and Medical Research Council guidelines for
the care of experimental animals. The derivation of Rb1F2/F2, TEC1,
and Trp53F2-10/F2-10 mice has been described elsewhere [23–25]. To
mediate deletion of loxP flanked (floxed) Rb1 (Rb1F2/F2) [23] and
Trp53 (Trp53F2-10/F2-10 ) alleles [25], Cre recombinase expression
was driven from the TEC1 transgene by using Tyrosinase (Tyr) tran-
scriptional elements [24]. The Tyr transcriptional elements are, or
were, active in the development in a subset of neural crest–derived tis-
sues including the adrenal medulla, melanocytes, and Schwann cells
of the peripheral nervous system, and this will target the loss of the
floxed Rb1 and Trp53 alleles specifically to these tissues [24]. Poly-
merase chain reaction (PCR) detection of the wild type, floxed,
and deleted alleles used Rb5/(5′-acctagcctgagagtaggcaac-3′)/Rbamp3-2
(5′-catctacagcaggtagatgccc-3′) and T008/T009/T011 primers for
Rb1 [23] and Trp53 [25], respectively.
The genetic backgrounds of the mice used to breed Rb1F2/F2:
Trp53F2-10/F2-10:TEC1, Rb1F2/+:Trp53F2-10/F2-10:TEC1, and Rb1F2/F2:
Trp53F2-10/F2-10 cohorts were as follows: the TEC1 transgenic mice were
backcrossed for 20 generations with C57BL/6J; the 129/SV:C57BL/6J
crossbred Rb1F2/F2 mice were backcrossed for a minimum of two gen-
erations with C57BL6/J before use. The Trp53F2-10/F2-10mice were ob-
tained from theNational Institutes ofHealthmouse repository andwere
on a FVB:129 background. Consequently, resultant mice from the
breeding program were a mixed C57BL/6J:FVB:129/SV background.
Tissue Culture
The medulla of Rb1F2/F2:Trp53F2-10/F2-10:TEC1 and Rb1F2/F2:
Trp53F2-10/F2-10 adrenal glands were physically decapsulated from
the cortex, minced, and enzymatically dissociated with trypsin.
The dissociated chromaffin cells were subsequently cultured in
Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA),
10% FBS, 2 mM L-glutamine, 100 U of penicillin, 100 μg of strep-
tomycin, and 100 μM nonessential amino acids.
Tissue Preparation and Immunohistochemistry
The Cre-expressing tissues including the adrenal glands and skin,
as well as a number of other tissues, including the heart, were dissected
from mice of appropriate genotype, washed in PBS, and then fixed
overnight at 4°C in 4% paraformaldehyde (Sigma, St Louis, MO)
in PBS. Samples were subsequently washed in PBS three times for
15minutes per wash, placed in 70% ethanol, and prepared for paraffin
blocks. Before paraffin blocking, the hearts were cut perpendicular to
their long axis at a point from their base equivalent to two-thirds
of their overall length. All tissue samples were paraffin-blocked, and
4-μm sections were subsequently cut onto SuperFrost plus slides
(HD Scientific, Wetherill Park, NSW, Australia). For histologic anal-
ysis, the slides from the adrenal glands and heart were subjected to
standard hematoxylin and eosin (H&E; HD Scientific) staining fol-
lowed by coverslipping.
To detect cellular proliferation, immunohistochemistry was per-
formed with antibodies against both MCM7 and Ki67, which detect
cellular proliferation. Tyrosine hydroxlase immunohistochemistry
was used to determine whether catecholamine synthetic pathways
were active in cells whereas antibodies against chromogranin A and
synaptophysin were used to determine the integrity of chromagenic
vessels that store catecholamines.
For MCM7, Ki67, tyrosine hydroxylase, chromogranin A, and syn-
aptophysin immunohistochemistry, the adrenal gland sections were
dewaxed in xylene (Ajax, Sydney, Australia) and rinsed in PBS, and
citrate retrieval of the antigen was performed in a pressure cooker using
10 mM citrate buffer (1.47 g of trisodium citrate dihydrate [Ajax] dis-
solved in 1 L of distilled water and adjusted to pH 6.0 with 1M sodium
hydroxide [Ajax]) by heating the slides to 125°C for 15minutes followed
by 10 seconds at 90°C. The sections were subsequently left to cool to
ambient temperature and rinsed with PBS. Endogenous peroxidase
activity in sections used for MCM7, tyrosine hydroxylase, chromogra-
nin A, and synaptophysin immunohistochemistry was neutralized using
3% H2O2/1% NaN3 (Sigma) in PBS for 30 minutes at 25°C.
Slides were rinsed in PBS twice, washed for a further 3 minutes,
and incubated in 10% goat serum (diluted in PBS) for 30 minutes at
25°C. The serum block was removed, and a 1:200 dilution of either
rabbit anti–chromogranin A (Zymed, South San Francisco, CA), rab-
bit anti–tyrosine hydroxylase (Chemicon, Temacula, CA), or rabbit
anti-MCM7 antibody (Abcam, Cambridge, UK) in PBS was added
and the slides were incubated overnight at 4°C. In the case of synap-
tophysin immunohistochemistry after the goat serum block, the
slides were washed three times in PBS for 5 minutes per wash, over-
laid with a 1:200 dilution of goat antimouse immunoglobulin class G
( Jackson ImmunoResearch Laboratories, West Grove, PA) in PBS for
30 minutes followed by three washes in PBS for 5 minutes per wash.
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A 1:4 dilution of the mouse monoclonal anti–synapthophysin antibody
(SY38; Abcam) was added, and the slides were slides incubated over-
night at 4°C.
At the completion of the overnight incubation, the slides were then
rinsed in PBS twice and washed for a further 3 minutes, and Dako
anti–Rabbit envision (Dako, Glostrup, Denmark) was added to the
MCM7, tyrosine hydroxylase, and chromogranin A slides, whereas
Dako antimouse envision (Dako) was used for the synaptophysin
slides. After a 30-minute incubation at 25°C, the slides were washed
quickly three times in PBS, given a final 5-minute wash, and were im-
mersed in DAB to develop color (2-10 minutes; the reaction was ter-
minated when the positive control included for each sample gave
obvious color development.). At the completion of incubation, slides
were rinsed in distilled water, counterstained with hematoxylin (HD
Scientific), washed in tap water, dehydrated, and coverslipped.
In the case of Ki67 (Dako), immunohistochemistry of the sectioned
adrenal glands was performed as described elsewhere [26].
Electron Microscopy
Electron microscopy of chromaffin cells obtained from Rb1F2/F2:
Trp53F2-10/F2-10:TEC1 and Rb1F2/F2:Trp53F2-10/F2-10 mice was per-
formed as described elsewhere [27].
Glyoxylic Acid Condensation Reaction
Adrenal glands from Rb1F2/F2:Trp53F2-10/F2-10:TEC1 and Rb1F2/F2:
Trp53F2-10/F2-10 mice were harvested, washed in PBS, and blocked
in optimal cutting temperature compound (Tissue Tek, Tokyo, Japan).
Glyoxylic acid condensation reactions, to detect biogenic amines, were
performed on 7-μm sections of these adrenal glands using the protocol
described by De la Torre [28].
Results
The Loss of Rb1 and Trp53 in Tyr-Expressing Tissues In Vivo
Leads to Adrenal Medulla Tumors
We have been interested in the role of the PP and Trp53 regulatory
axis in maintaining the homeostasis of the neural crest–derived tis-
sues. To this end, we have been using floxed Rb1 (Rb1F2/F2) [23] and
Trp53 (Trp53F2-10/F2-10) [25] mice crossed with TEC1+/− (tyrosinase-
expressing Cre) transgenic mice to drive Cre recombinase expression
and ablation of these floxed alleles in Tyrosinase transcriptional do-
mains. This yields a tissue-specific knockout in neural crest–derived
tissues that actively express Tyrosinase or have done so at any given
stage in their development, in this case the adrenal medulla, melano-
cytes, and Schwann cells of the peripheral nervous system [24]. To
examine the cell autonomous effects of Rb1 and Trp53 loss in these
tissues, cohorts of Rb1F2/F2:Trp53F2-10/F2-10:TEC1+/−, Rb1F2/+:
Trp53F2-10/F2-10:TEC1+/−, and floxed control animals (n = 13 for each
group) were bred at the expected Mendelian ratios from the parental
strains and were phenotypically examined over an 8-month time
frame. Within this study, all floxed control animals remained viable
and healthy. Of the 13 mice from the Rb1F2/+:Trp53F2-10/F2-10:
TEC1+/− cohort, 2 did not survive the time course. One of these ani-
mals required euthanasia owing to a seemingly unrelated problem
(bowel blockage), and we were unable to determine the cause of death
underpinning the other mortality. In contrast, none of the Rb1F2/F2:
Trp53F2-10/F2-10:TEC1+/− animals survived beyond 8 months, with
the median survival time being 121 days (Figure 1A).
The mortality of the Rb1F2/F2:Trp53F2-10/F2-10:TEC1+/− animals
was not due to melanocytic lesions because none of the cohort showed
pigmentation defects or melanoma, although the melanocytes were
Rb1 and Trp53-null [29]. This was surprising because the PPs and
Trp53/Mdm2/Arf regulatory axes are presumed to fulfill an integral
role in melanocyte homeostasis. It was also significant that within
the Rb1F2/F2:Trp53F2-10/F2-10:TEC1+/− cohort, 10 of the 13 mice ap-
peared asymptomatic before death. They had no obvious external
macroscopic masses, distal metastasis, or wasting, and there was no
obvious physical predictor of impending death. Consequently, when
necroscopy was performed, particular attention was paid to whether
perturbations existed in the remaining Cre recombinase expressing tis-
sues (i.e., the adrenal medulla or peripheral nervous system). In this
context, it was observed that all of the Rb1F2/F2:Trp53F2-10/F2-10:
TEC1+/− mice had enlarged adrenal glands compared with Rb1F2/+:
Trp53F2-10/F2-10:TEC1+/− and Rb1F2/F2:Trp53F2-10/F2-10 control animals
(Figure 1, B and C ) and this was invariably bilateral. The enlarged
adrenal glands remained encapsulated by the cortex and did not inter-
digitate into or invade surrounding tissues, and consistent with the
aforementioned absence of external distal metastasis, no other gross le-
sions were apparent in other internal tissues examined.
The remaining Rb1F2/F2:Trp53F2-10/F2-10:TEC1+/− mice also pos-
sessed bilateral enlarged adrenal glands but, in contrast to the remain-
der of the cohort, they also displayed wasting, and tumor masses were
present in regions remote from the adrenal gland. In two of these cases,
the locality of the tumor masses was consistent with the trigeminal
nerve–derived schwannomas described for Prkra1F/F:TEC3 mice
[30] (data not shown). The third case seemed an exception to the rest
of the cohort because it possessed a tumor mass localized to the neck
region, which may have represented a distal metastasis from the adre-
nal glands.
Because the only overt defect in most Rb1F2/F2:Trp53F2-10/F2-10:
TEC1+/−mice was the adrenal glands, this tissue was subjected to further
characterization. The histologic analysis of Rb1F2/F2:Trp53F2-10/F2-10
adrenal glands indicated that the chromaffin cells all had nuclei of con-
sistent size and shape (Figure 1D). In contrast, at time points as early as
56 days postpartum, the Rb1F2/F2:Trp53F2-10/F2-10:TEC1 medulla
showed distinct foci or clusters of cells with atypical H&E staining
and aberrant nuclear morphology (Figure 1E ). They possessed highly
variable nuclear shape and volume, ranging from smaller irregularly
shaped nuclei through to large polymorphic nuclear aggregates
(Figure 1F ). This is similar to cultured Rb1F2/F2:Trp53F2-10/F2-10:
TEC1 melanocytes, where the loss of Rb1 and Trp53 causes cells to
rapidly become hypoploid and hyperploid owing to defects in mitosis,
such as multipolar mitosis and cytokinesis [29].
This suggests that the mice initially develop hyperplastic foci of adre-
nal medulla chromaffin cells that rapidly progress to PCC by 112 days
because the entire volume of the medulla was occupied by these atypical
cells, and the cortex was significantly compressed (Figure 1G ). The
overall tissue architecture of the Rb1F2/F2:Trp53F2-10/F2-10:TEC1 adre-
nal medullas also seem typical for PCC, being heterogeneous with both
the expected zellballan and trabeculae configurations being noted (data
not shown). The highly proliferative status of Rb1F2/F2:Trp53F2-10/F2-10:
TEC1 chromaffin cells was illustrated by the expression of the prolif-
eration marker Ki67 (Figure 1H ), which was absent in controls
(Figure 1I ). An identical result was also obtained with another prolif-
erative marker, MCM7 (data not shown).
To confirm that the chromaffin cells from Rb1F2/F2:Trp53F2-10/F2-10:
TEC1mice were Rb1 andTrp53 null, they were cultured and subjected
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to PCR analysis using primers that detect both the floxed and deleted
Rb1 and Trp53 alleles. The Rb1F2/F2:Trp53F2-10/F2-10:TEC1 cell line
amplified the 329- and 612-bp PCR products corresponding to the
deleted Rb1 (Figure 1J , lane 2) and Trp53 alleles (Figure 1J , lane 5 ),
respectively. No bands corresponding to the product from the floxed
allele were apparent, unlike the PCR of chromaffin cell DNA from
Rb1F2/F2:Trp53F2-10/F2-10 animals (Figure 1J , lanes 3 and 6 ), indicating
that the cultured cells had undergone complete Cre-mediated deletion
of the floxed Rb1 and Trp53 alleles.
In summary, these data show that the loss of Rb1 and Trp53 in the
adrenal medulla of Rb1F2/F2:Trp53F2-10/F2-10:TEC1 mice, as driven
by Cre expression from the TEC1 transgene, underpin chromaffin
cell hyperplasia and the rapid onset of bilateral PCC with 100% pen-
etrance. To determine whether PCC is responsible for the phenotype
of the Rb1F2/F2:Trp53F2-10/F2-10:TEC1 mice, the adrenal medullas of
these animals were subjected to further characterization.
Rb1−/−:Trp53−/− Adrenal Chromaffin Cells Actively Synthesize,
but May Not Be Able to Appropriately Store, Catecholamines
Because PCCs are typically benign tumors whose negative physi-
ological impact is exerted by paroxysmal hypertensive episodes result-
ing from inappropriate catecholamine release [31,32], our analysis
focused on aspects of chromaffin cell biology pertaining to these issues.
The enzymatic systems required for catecholamine synthesis seem to
be relatively intact in Rb1−/−:Trp53−/− chromaffin cells because the
expression of tyrosine hydroxylase, a key enzyme in catecholamine
catabolism, was intact in Rb1F2/F2:Trp53F2-10/F2-10 (Figure 2A) chro-
maffin cells and was readily detectable, albeit at slightly reduced levels,
in the medullas of Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (Figure 2B) mice.
The presence of these enzymatic systems translated into the produc-
tion of functional bioamines because they could be detected by virtue
of the fluorescence generated by the glyoxylic condensation reaction
assay when it was performed on sections of unfixed adrenal gland tissue
from theRb1F2/F2:Trp53F2-10/F2-10 (Figure 2C),Rb1F2/+:Trp53F2-10/F2-10:
TEC1 (Figure 2D), and Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (Figure 2E )
mice, compared with controls (Figure 2F ).
To determine whether the catecholamines were correctly stored,
the adrenal medullas of Rb1F2/F2:Trp53F2-10/F2-10 and Rb1F2/F2:
Trp53F2-10/F2-10:TEC1 mice were subjected to immunohistochemistry
for chromogranin A and synaptophysin, both components of chromaf-
fin cell secretory vesicles. Unlike the Rb1F2/F2:Trp53F2-10/F2-10 controls
(Figure 3, A andC ), the adrenal medullas of Rb1F2/F2:Trp53F2-10/F2-10:
TEC1 mice lacked strong chromogranin A (Figure 3B) and synapto-
physin (Figure 3D) staining, although a somewhat diffuse pattern was
Figure 2. The effect of compound Rb1 and Trp53 loss on catechol-
amine synthesis in the adrenal chromaffin cells. The integrity of
catecholamine biosynthetic pathways in Rb1F2/F2:Trp53F2-10/F2-10
(A) and Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (B) adrenal glands was exam-
ined by immunohistochemical detection of tyrosine hydroxylase.
Glyoxylic condensation reactions to detect active biogenic amines
were performed on the adrenal glands from Rb1F2/F2:Trp53F/F (C),
Rb1F2/+:Trp53F/F:TEC1 (D), and Rb1F2/F2:Trp53F/F:TEC1 (E) mice.
As a control, the experiment was performed using a serial section
from the Rb1F2/F2:Trp53F/F:TEC1 adrenal gland, and the glyoxylic
acid was omitted from the reaction (F).
Figure 1. The compound loss of Rb1 and Trp53 in mouse Tyr transcriptional domains profoundly shortens the life span of Rb1F2/F2:
Trp53F2-10/F2-10:TEC1 mice by potentially inducing PCC. A Kaplan-Meier survival curve was constructed for Rb1F2/F2:Trp53F2-10/F2-10:
TEC1 (Rb1:Trp53-TSKO) mice versus Rb1F2/+:Trp53F2-10/F2-10:TEC1 (Trp53-TSKO) and floxed (wild type) control animals. With n = 13
in each group, data are shown to be statistically significant (P < .0001) with a median survival of double knockouts being 121 days
(A). The adrenal glands from 16-week-old Rb1F2/F2:Trp53F2-10/F2-10 (left) and Rb1F2/+:Trp53F2-10/F2-10:TEC1 (middle) mice are smaller than
those of Rb1F2/F2:Trp53F2-10/F2-10:TEC1 mice (B). For further dimensional perspective, Rb1F2/F2:Trp53F2-10/F2-10 adrenal gland (left) and
Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (right) adrenal glands are shown still attached to the kidneys (C). H&E-stained paraffin sections of chromaffin
cells from Rb1F2/F2:Trp53F2-10/F2-10 adrenal medullas showing that they are of very consistent size and shape (D). Scale bar, 50 μm. Histologic
analysis of 56 days postpartum Rb1F2/F2:Trp53F2-10/F2-10:TEC1 adrenal glands shows distinct foci of hyperplastic cells (arrow) (E). Higher
magnification of the hyperplastic Rb1F2/F2:Trp53F2-10/F2-10:TEC1 chromaffin cells showing a lack of uniformity in nuclei size, with both smaller
nuclei (black arrow 1) and large polyploid nuclear aggregations apparent (black arrow 2) (F). Scale bar represents 50, 50 μm. By 112 days post-
partum, the adrenal medulla was essentially completely occupied by transformed cells and the cortex was compressed (G). Cellular prolifer-
ation in Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (H) and Rb1F2/F2:Trp53F2-10/F2-10 (I) adrenal glands was assessed by Ki67 immunohistochemistry.
Scale bar, 200 μm. To determine the status of Rb1 and Trp53 alleles in the chromaffin cells derived from Rb1F2/F2:Trp53F2-10/F2-10:TEC1
mice and those extracted from Rb1F2/F2:Trp53F2-10/F2-10 adrenal glands, they were PCR-genotyped with the Rb5-2/Rbamp2-2/Rbamp3-2 and
T008/T009/T011 primer combinations to amplify products from the Rb1 and Trp53 alleles, respectively (J). Lane designations are as fol-
lows: 1, 1-kb ladder; 2-4, Rb1 genotyping for Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (2), Rb1F2/F2:Trp53F2-10/F2-10 (3), and negative control (4); 5-7,
Trp53 genotyping for Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (5), Rb1F2/F2:Trp53F2-10/F2-10 (6), and negative control (7).
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obtained in each case. To confirm this result and ascertain whether
compromised synaptophysin expression was common in Rb1−/−:
Trp53−/− chromaffin cells, further adrenal glands from Rb1F2/F2:
Trp53F2-10/F2-10:TEC1 mice (n = 5) were subjected to synaptophysin
immunohistochemistry. The expression levels of synaptophysin
seemed to be highly variable between both PCCs and even within a
given sample. However, whereas synaptophysin always seemed pres-
ent, it was generally at much lower levels than in normal adrenal
medullas (data not shown).
To more closely examine the ultrastructure of Rb1−/−:Trp53−/−
chromaffin cells, with a specific emphasis on chromagenic vesicles,
they were subjected to electron microscopy. The control Rb1F2/F2:
Trp53F/F chromaffin cells possessed a high concentration of electron
dense chromagenic granules (Figure 3E ). In contrast, the Rb1F2/F2:
Trp53F/F:TEC1 chromaffin cells had smaller vesicles, but these adopted
an almost halo-like appearance and lacked any electron dense material
(Figure 3F). These data show that whereas the Rb1F2/F2:Trp53F/F:TEC1
chromaffin cells have vesicles typical of pheochromocytes, their func-
tional integrity may be compromised, as indicated by the chromo-
granin A and synaptophysin immunohistochemistry, so they do not
store catecholamines at a capacity or in a way typical of normal chro-
maffin cells.
The inappropriate catecholamine release deriving from PCC can
have profound structural effects on the heart [31,32]. Consequently,
hearts were taken from 3.5-month-old Rb1F2/F2:Trp53F/F:TEC1 and
Rb1F2/F2:Trp53F/F mice (n = 3 for each genotype), sectioned and ex-
amined for obvious defects. In contrast to the hearts from Rb1F2/F2:
Trp53F/F, which all appeared normal (Figure 3G ), structural remodel-
ing of the left ventricle was apparent in all Rb1F2/F2:Trp53F/F:TEC1
hearts (Figure 3H ). Because the heart does not express the Cre trans-
gene, these secondary changesmay be PCC-derived.Overall, the pheno-
type described for the Rb1F2/F2:Trp53F2-10/F2-10:TEC1+/− mice is
consistent with that expected for PCC because it indicates that they
may succumb to the catecholamine-induced effects of benign PCC,
highlighting the important role that the Rb1 and Trp53 tumor sup-
pressor genes fulfill in chromaffin cell homeostasis.
Discussion
PCC is a relatively rare and typically benign tumor type [33,34]. De-
spite this, they are clinically significant because their overproduction of
catecholamine can result in potentially lethal paroxysmal or sustained
hypertensive episodes [31,32].
Insights into the genetic basis and molecular mechanisms that govern
the maintenance of chromaffin cell homeostasis have been provided by
the identification of genes mutated in familial PCC syndromes, which
include NF1, RET, VHL, or SDH [35]. PCCs are also observed when
general tumor suppressor genes, such as p18 and Pten, are mutated.
Mice mutant for p18 and Pten develop PCC at frequencies of 14%
and 65%, respectively [36], but the percentage can be significantly
heightened when p18 and Pten are either comutated or mutated in
combination with other tumor suppressor genes (e.g., p18−/−:p27−/−,
p18−/−:Pten+/−, p27−/−:Pten−/−, and Pten+/−:Ink4a/arf +/− compound
mutant mice develop PCC at frequencies of 91% [6], 84% [36],
100% [37], and 81% [7], respectively). This indicates that a significant
degree of synergism exists between these tumor suppressive pathways
in maintaining chromaffin cell homeostasis.
A common point of action of these genes is their ability to mod-
ulate Cdk-cyclin function (as reviewed in Tonks et al. [14]). Indicat-
ing that loss of normally stringent Cdk-cyclin regulation at multiple
points in the cell cycle of chromaffin cells may be an important factor
for PCC development. The primary targets of Cdk-cyclin function in
cell cycle regulation are the PPs, indicating that they may have a key
role in chromaffin cell homeostasis. Indeed, the perturbation of PP
function may also be integral to the manifestation of familial PCC
Figure 3. To assess the status of catecholamine storing vesicles,
immunohistochemistry was performed for chromogranin A in
Rb1F2/F2:Trp53F2-10/F2-10 (A) and Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (B)
and synaptophysin in Rb1F2/F2:Trp53F2-10/F2-10 (C) and Rb1F2/F2:
Trp53F2-10/F2-10:TEC1 (D) adrenal medullas. Scale bar, 50 μm. Elec-
tron micrographs of Rb1F2/F2:Trp53F/F (E; original magnification,
×50,000) and Rb1F2/F2:Trp53F/F:TEC1 (F; original magnification,
×50,000) chromaffin cells showing the overall density andmorphol-
ogy of vesicles (arrow). H&E staining of Rb1F2/F2:Trp53F2-10/F2-10 (G)
and Rb1F2/F2:Trp53F2-10/F2-10:TEC1 (H) heart sections that shows
structural remodeling of the Rb1F2/F2:Trp53F2-10/F2-10:TEC1 hearts
(as indicated by arrows).
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syndromes as the mutation of RET, NF1, or VHL contribute to in-
creased Cdk-cyclin function and decreased PP function by a number
of mechanisms, such as decreased CKI levels, increased cyclin and
Cdk expression, or decreased expression of other Cdk-cyclin inhibi-
tors, for example, 14-3-3-epsilon [38–45].
Because Rb1 is known to have the most significant tumor suppres-
sive function of the PP family, it is likely that its functional integrity
is integral to adrenal chromaffin cell homeostasis. Indeed, support for
this theory comes from the phenotype of Rb1−/−:Rb1+/+ chimeric mice,
where 67% developed hyperplastic nodules of the adrenal medulla
before succumbing to pituitary gland tumors at 6 months [19,46].
Further, a study of Rb1+/− mouse cohorts by Nikitin et al. [18] indi-
cated that 71% of Rb+/− heterozygous mice developed PCC, with 14%
of those being bilateral. It must be noted, however, that the lesions
classified as PCC included those that appear as small foci of atypical
cells. Consequently, Nikitin et al. [18] may be overestimating the fre-
quency of PCC; as such, lesions would usually be classified as chro-
maffin cell hyperplasia [20]. Significantly, however, the hyperplastic
cells noted early in the course of the disease had loss of heterozygosity
for the remaining wild-type Rb1 allele, supporting the findings from
Rb1−/−:Rb1+/+ chimeras. Furthermore, data derived from human PCC
show that, despite Rb1 loss being relatively common, there is no sig-
nificant difference between Rb1-positive and -negative PCCs in malig-
nant potential and survival of patients [21]. This indicates that the rate
of conversion from chromaffin cell hyperplasia to PCC driven by Rb1
loss can be enhanced by the mutation of other genetic modifiers.
Other PPs are obvious candidate tumor suppressor genes that may
interact with Rb1 in the progression of PCC. Indeed, the loss of Rbl2,
but not Rbl1, can exacerbate the development and decrease the latency
of PCC development occurring in Rb1-deficient mouse models [13].
We have now shown that Trp53, another gene involved in maintaining
genomic integrity, can also synergize with Rb1 loss in the development of
PCC. This was obvious in vitro, as Rb1−/−:Trp53−/− chromaffin cells were
readily established in culture, whereas Rb1−/− or Trp53−/− cells could not
be cultured under the same conditions. Concordantly, the in vivo com-
pound loss of these two genes had a profound effect, yielding bilateral
PCCs in all Rb1F2/F2:Trp53F/F:TEC1 individuals examined to date.
Whereas Rb1 loss is important at the level of cellular proliferation
and hyperplasia during the initial stages of PCC development, the role
of Trp53 has been controversial. For example, Trp53 mutation has
been identified in PCC [21], but a recent study by Petri et al. [47]
of benign and malignant PCC using CGH coupled to immunohisto-
chemistry showed that Trp53 function does not contribute significantly
to the development of PCC. In our study, Rb1F/+:Trp53F/F:TEC1
mice, like Rb1+/−:Trp53−/ and Trp53−/− mice described elsewhere
[48,49], did not get PCC at any substantial frequency, but the
Rb1F2/F2:Trp53F2-10/F2-10:TEC1 cohort succumbed to the disease with
complete penetrance. Consequently, Trp53 is significant to PCC de-
velopment, but only when this occurs on a background of predisposing
mutations, such as Rb1.
There are a number of potential mechanisms by which Trp53 mu-
tation may act synergistically with Rb1 loss in the development of
PCC. In the first, the Trp53/Arf/Mdm2 regulatory axis can exert a di-
rect effect on the overall PP function (reviewed in Tonks et al. [14]).
Consequently, compound loss of Rb1 and Trp53 functions in the de-
velopment of PCC may be similar to that caused by Rb1 and Rbl2.
In the second instance, recent work has suggested thatTrp53 loss may
act to fundamentally change the metabolism of tumor cells to expedite
neoplastic transformation. Tumor cells use anaerobic glycolysis as a pri-
mary metabolic pathway, even under normal aerobic conditions, and
this phenomenon, known as the Warburg effect, confers a proliferative
advantage to the mutated cells by allowing the increased synthesis of
biomolecules integral to proliferation [50]. The Warburg effect may
be enhanced in Trp53-null cells by a number of mechanisms.
First, Trp53 loss in VHL-related (familial) PCC may lead to a hyp-
oxic growth response through promiscuous hypoxia-inducible factor
activation in tumor cells, so that they primarily use glycolysis as their
energy source [51]. This potentially reconciles our results on Trp53
with familial PCC because VHL is known to bind Trp53 and protect
it from degradation. This may not just appropriately maintain aerobic
respiration but, in response to genotoxic stress, it potentiates Trp53-
mediated transcriptional activity, cell cycle arrest, and apoptosis, all of
which are integral to cellular homeostasis [51,52].
Second, Trp53-loss may inhibit the expression of key genes in-
volved in aerobic respiration, such as Sco2 and TIGAR. Sco2 is the
cytochrome c oxidase assembly factor necessary for oxygen consump-
tion and the activity of the oxidative phosphorylation IV complex [53],
whereas TIGAR expression acts to downregulate glycolysis, and they
could act in a concerted manner to inhibit the Warburg effect [54].
Third, the loss of Trp53 can also cause depletion of mitochondrial
DNA and associated mitochondrial mass, presumably leading to re-
duced mitochondrial oxidative capacity [55].
Collectively, this suggests that Trp53 mutation may potentially ex-
acerbate PCC development in Rb1F2/F2:Trp53F2-10/F2-10:TEC1 mice
at a number of levels, including decreased PP function by a number
of mechanisms as well as by establishing a metabolic environment
permissible to the Warburg effect and tumor growth.
Despite the apparent proliferative capacity of Rb1−/−:Trp53−/−
chromaffin cells, the resultant PCCs are generally benign and do not
metastasize. Nonetheless, they seem to manifest a profound effect on
mouse physiology, presumably at the cardiac level, which seems to re-
sult from the inability of the PCCs to appropriately store the catecho-
lamines that they synthesize. Ultimately, this shows that the synergistic
effects of Rb1 and Trp53 are essential in maintaining both adrenal
chromaffin cell homeostasis and animal vitality.
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